Cholesterol-lowering drugs may not prevent Alzheimer's disease

Jan 16, 2008

Contrary to some reports, taking statins, which are cholesterol-lowering drugs, offers no protection against Alzheimer’s disease, according to research published in the January 16, 2008, online issue of Neurology, the medical journal of the American Academy of Neurology.

The study involved 929 Catholic clergy members who were an average of 75 years old, free of dementia at the beginning of the study and enrolled in the Religious Orders Study, an ongoing study of aging and Alzheimer’s disease. All of the participants agreed to a brain autopsy at the time of their death and underwent annual cognitive tests for up to 12 years.

At the beginning of the study, 119 people were taking a statin. During the 12-year follow-up period, 191 people developed Alzheimer’s disease, of whom 16 used statins at the start of the study.

“Some studies have suggested people taking cholesterol-lowering drugs are less likely to have Alzheimer’s disease, but our longitudinal findings found no relation between statin use and Alzheimer’s,” said study author Zoe Arvanitakis, MD, MS, Associate Professor of the Department of Neurological Sciences at Rush University Medical Center in Chicago and member of the American Academy of Neurology. “The study also found no association between taking statins and a slower cognitive decline among older people.”

In addition, researchers performed brain autopsies on more than 250 people who died during the study to examine the relation of statins to Alzheimer’s disease pathology and stroke in the brain, the two common pathological causes of dementia. The study found statin use at any time during the course of the study had no effect on pathology of Alzheimer’s disease or strokes.

Arvanitakis says the study is limited in that there were relatively few statin users among those who died. She says future studies will need to look at the possibility of associations of statins with other pathologic changes of Alzheimer’s disease not examined in this study.

Source: American Academy of Neurology

Explore further: FDA investigates deaths of patients on antipsychotic drug

add to favorites email to friend print save as pdf

Related Stories

Toxic radiation in groundwater at Fukushima: operator

1 hour ago

Cancer-causing radioactive substances have been found in groundwater at the crippled Fukushima nuclear plant, its Japanese operator said on Wednesday, as it pledged to prevent it getting into the sea.

City-life changes blackbird personalities, study shows

9 hours ago

The origins of a young animal might have a significant impact on its behavior later on in life. Researchers at the Max Planck Institute for Ornithology in Radolfzell, Germany, have been able to demonstrate ...

Origins of 'The Hoff' crab revealed (w/ Video)

9 hours ago

The history of a new type of crab, nicknamed 'The Hoff' because of its hairy chest, which lives around hydrothermal vents deep beneath the Southern Ocean and Indian Ocean, has been revealed for the first ...

Research shows moves to ban pay-to-delay deals are justified

9 hours ago

Controversial deals that delay generic versions of drugs coming onto the market can lead to consumers paying significantly more for some treatments, according to new research by an academic from the University of East Anglia ...

Recommended for you

Protalix signs supply deal with Brazilian govt

Jun 19, 2013

Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's Gaucher disease ...

EU fines pharma firms over generics delay (Update)

Jun 19, 2013

(AP)—The European Union has fined Danish pharmaceuticals multinational Lundbeck and several other producers a combined 146 million euros ($195 million) for delaying the market entry of cheaper generic alternatives ...

Investigational drug improves sleep disorder among the blind

Jun 17, 2013

An investigational new drug significantly improved a common and debilitating circadian rhythm sleep disorder that frequently affects people who are completely blind, a multicenter study finds. The results were presented Monday ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

SDMike
not rated yet Jan 17, 2008
Either this abstract or the original report is very poor. Only some statins are claimed to reduce the onset age of dementia. With out reporting the specific statins observed and unless the study used a factor analysis design where the specific statin chemical was a variable, the study tells us nothing. The headline and conclusion is BOGUS.

More news stories

Explainer: What is foreign accent syndrome?

In the past few days, a great deal of media attention has been paid to Leanne Rowe, a Tasmanian woman who has lived eight years with a French accent she acquired after a car accident. This phenomenon is known ...

Key link found in Cosmic Distance Ladder

(Phys.org) —When observing the bright explosion of a White Dwarf star in our neighbouring galaxy last year, researchers from The Australian National University collected the largest ever data set on what ...

CERN's ISOLTRAP reveals new magic in the atomic nucleus

(Phys.org) —The ISOLTRAP collaboration has measured the mass of exotic calcium nuclei using a new instrument installed at the ISOLDE facility at CERN. The measurements, published on 20 June in the journal Nature, clearl ...